In Brief: Everest Medical
This article was originally published in The Gray Sheet
Executive Summary
Everest Medical: Firm plans to introduce the BiSECTOR 5 mm bipolar ligating forceps for use in coagulation of vessels during electrosurgery and to transect vessel tributaries prior to saphenous vein harvesting at the Jan. 23-25 Association of Physician Assistants in Cardiovascular Surgery meeting and the Society of Thoracic Surgery conference Jan. 26-28, both of which are being held in New Orleans. The company also is debuting an Everest-branded version of its bipolar scissors. Everest will market the instruments "for use with non-Guidant saphenous vein harvesting approaches and systems," the company says in a Jan. 20 release. The company entered a supply agreement with Guidant in June 1997 to market Everest instruments with Guidant's minimally invasive saphenous vein harvesting system...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.